Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort

Zoé Van de Wyngaert(Centre Hospitalier Universitaire de Lille), S. Alfandari(Centre Hospitalier de Tourcoing), Sarah Bonnet(Hôpital Saint Eloi), Paul Chauvet(Centre Hospitalier Universitaire de Lille), Guillaume Escure(Université de Lille), Alexandre Willaume(Hôpital Saint-Vincent-de-Paul), Nicolas Branche(Centre Hospitalier Universitaire de Lille), Ines Arib(Centre Hospitalier Universitaire de Lille), Benjamin Carpentier, Kevin James Wattebled(Centre Hospitalier Universitaire de Lille), Houria Debarri(Centre Hospitalier Universitaire de Lille), Bruno Quesnel(Inserm), Loïc Renaud(Assistance Publique – Hôpitaux de Paris), Morgane Nudel(Centre Hospitalier Universitaire de Lille), Marie Titécat(Centre Hospitalier Universitaire de Lille), Céline Berthon(Université Paris-Sud), Charline Legrand(Centre Hospitalier Universitaire de Lille), Sarah Barbieux(Centre Hospitalier Universitaire de Lille), Jean‐Baptiste Bossard(Centre Hospitalier Universitaire de Lille), Claire Bories(Guy's and St Thomas' NHS Foundation Trust), Arthur Simonnet(Centre Hospitalier Universitaire de Lille)
International Journal of Antimicrobial Agents
March 1, 2019
10.1016/j.ijantimicag.2019.02.020
Cited by 27

Related Papers

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
|Blood|1994|581
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
|Blood|2007|575
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
|Leukemia|2011|464
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431